In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Paradigm Therapeutics gets £12mm in second round

Executive Summary

University of Cambridge spin-off Paradigm Therapeutics (functional genomics) raised £12mm ($19mm) in a second round private placement co-led by BioMedical Sciences Investment Fund and Technomark Medical Ventures. Also participating was return investor Avlar BioVentures as well as Genmab, whose investment is the result of an April 2002 agreement with Paradigm to develop antibody therapeutics.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
      • Bioinformatics
      • Genomics-Proteomics
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies